Business Remedies | Rajshree Upadhyaya | By changing the way patients with critical health conditions and post-transplant cases are monitored, Agragesh and Avinash Ramani established their identity by starting the diagnostics platform Trunome, which could replace biopsy with a simple blood test. It was initiated as a solid, determined effort. One brother brought business strategy and scale understanding, while the other brought deep expertise in molecular biology and clinical science. Their original venture, Acranolife Genomics, turned that idea into a product named Trunome, which focused on circulating cell-free DNA and genomic signals in blood as a means of detecting organ stress, rejection, and infection compared to traditional methods. The brothers carried that conviction to the stage of Shark Tank India, where instead of a flashy consumer pitch, they presented clinical data, patient details, and a clear adoption path. They sought capital around a valuation that reflected invested research, patents, and early validation efforts, and this seriousness shifted the tone of the meeting.
In the television conversation, empathy for patient needs was balanced with tough questions about sample size, reproducibility, and regulatory approvals. Investors scrutinized pricing, lab capacity, and pathways to hospitals, while the founders explained how Trunome’s assays had been conducted on thousands of samples and how early hospital partnerships were already helping build clinical trust.
Priority to sequential pilots
After the cameras turned off, the difficult work of clinical adoption and operational expansion began in earnest. For a diagnostics company, the journey from prototype to platform meant investing in lab infrastructure, quality control, data pipelines, and physician education-and the Ramani brothers contributed to each of these tasks. They made affordability a part of their mission. In Western markets, advanced genomic tests were often beyond the reach of many Indian patients, and Trunome’s business model aimed to make these capabilities accessible to a larger population. This meant negotiating costs, standardizing processes for reproducibility, and showing doctors that blood-based genomic signals could be translated into practical clinical decisions rather than noise.
The road ahead also required dealing with regulatory and privacy issues tied to genomic work. Building trust with hospitals required not just patents and validation, but also transparent protocols for collaborations that provided patient data and peer-reviewed evidence. The founders chose the long-term game, prioritizing sequential pilots in specialized centers and physician approvals over quick consumer launches.
This patient- and evidence-first approach shaped the conversation about their success. Incremental wins in hospital corridors, repeatable lab results, and measurable improvements in patient monitoring proved to be the most important milestones.
Turning laboratory insight into a practical tool
What makes Trunome’s story compelling is the blend of sibling chemistry, scientific rigor, and clear social ambition. This is not a story of overnight scale or rapid consumer fame, but of two founders who turned laboratory insights into a practical tool that could transform clinical practice for transplant recipients and chronic patients. Their appearance on television accelerated visibility and opened new doors, but the company’s future will be determined in laboratories and wards, where reproducibility, physician conviction, and sustainable pricing decide whether a new test becomes standard practice. If Trunome continues on the path set by the Ramani brothers-steady, evidence-based, and patient-centered-their work could quietly redefine non-invasive monitoring in India and, over time, in comparable healthcare systems elsewhere.
Written & Edited By:
Rajshree Upadhyaya
